Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: A retrospective cohort study

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 8, 2010, Pages 1779-1783

  Goldberg, Elad ^a,b   Paul, Mical ^a,b   Talker, Olga ^a   Samra, Zmira ^a   Raskin, Maria ^a   Hazzan, Rawi ^a   Leibovici, Leonard ^a,b   Bishara, Jihad ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Glycopeptides; MRSA; Outcomes; Staphylococci; Trimethoprim sulfamethoxazole

Indexed keywords

COTRIMOXAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOREIGN BODY; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; PHENOTYPE; SEPSIS; ADOLESCENT; BACTEREMIA; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BLOOD; COHORT STUDIES; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VANCOMYCIN; YOUNG ADULT;

EID: 77954691795     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq179     Document Type: Article

References (29)

1. Noskin GA, Rubin RJ, Schentag JJ et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005; 165: 1756-61.
2. Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl 2: S114-32.
3. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12 Suppl 1: 16-23.
4. Chang S, Sievert DM, Hageman JC et al. Infection with vancomycinresistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-7.
5. Kaka AS, Rueda AM, Shelburne SA et al. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 680-3.
6. Elwell LP, Wilson HR, Knick VB et al. In vitro and in vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1986; 29: 1092-4.
7. Bishara J, Pitlik S, Samra Z et al. Co-trimoxazole-sensitive, methicillinresistant Staphylococcus aureus, Israel, 1988-1997. Emerg Infect Dis 2003; 9: 1168-9.
8. Styers D, Sheehan DJ, Hogan P et al. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5:2.
9. Tsuji BT, Rybak MJ, Cheung CM et al. Communityand health care-associated methicillin-resistant Staphylococcus aureus:a comparison of molecular epidemiology and antimicrobial activities of various agents. Diagn Microbiol Infect Dis 2007; 58:41-7.
10. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390-8.
11. Bengtsson E, Svanbom M, Tunevall G. Trimethoprim-sulphamethoxazole treatment in staphylococcal endocarditis and Gram-negative septicemia. Scand J Infect Dis 1974; 6:177-82.
12. Seligman SJ, Madhavan T, Alcid D. Trimethoprim-sulfamethoxazole in the treatment of bacterial endocarditis. J Infect Dis 1973; 128 Suppl: 754-61.
13. Shafqat SH, Shah SA, Seyed SA. Bacterial endocarditis over prosthetic valves treated with trimethoprim-sulphamethoxazole combination. Br Heart J 1971; 33: 974-6.
14. Tamer MA, Bray JD. Trimethoprim-sulfamethoxazole treatment of multiantibiotic-resistant staphylococcal endocarditis and meningitis. Clin Pediatr (Philadelphia) 1982; 21: 125-6.
15. Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984; 100: 881-90.
16. Yeldandi V, Strodtman R, Lentino JR. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother 1988; 22: 873-80.
17. de Gorgolas M, Aviles P, Verdejo C et al. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother 1995; 39: 953-7.
18. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46: 584-93.
19. Adra M, Lawrence KR. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections.Ann Pharmacother 2004; 38: 338-41.
20. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-32.
21. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007; 45 Suppl 3: S184-90.
22. Schulte B, Heininger A, Autenrieth IB et al. Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium. Epidemiol Infect 2008; 136: 1131-3.
23. Reid GE, Grim SA, Aldeza CA et al. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27: 1198-201.
24. Silverman JA, Mortin LI, VanPraagh AD et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149-52.
25. Nichols RL, Graham DR, Barriere SL et al. Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999; 44: 263-73.
26. Fagon J, Patrick H, Haas DW et al. Treatment of Gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161: 753-62.
27. Dodds TJ, Hawke CI. Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis). ANZ J Surg 2009; 79: 629-35.
28. Yamaoka T. The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA. J Infect Chemother 2007; 13: 141-6.
29. Aldridge KE, Gelfand MS, Schiro DD et al. The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobial agents. Diagn Microbiol Infect Dis 1992; 15: 601-8.